← Changchun High & New Technology Industries overview

Changchun High & New Technology Industries vs Shanghai Fosun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Changchun High & New Technology Industries Group Inc (000661.CS)

Q3 2026
▲3▼1

Profit Halved, but Drug Pipeline and Global Deal Advance

  • Interim Profit Halved First-half 2026 net profit fell 51.64% to 475 million yuan as revenue dropped 16.06%. This is the single biggest drag on the stock because it shows the core business is shrinking, even though operating cash flow rose 40.92%.

    The profit decline is the main negative force on the stock this period.

  • Pipeline Wins Keep Coming The company's GeneScience unit won Chinese regulatory acceptance or approval for four new drug candidates: Jintuoximab for gastric cancer, GenSci136 for lupus, GenSci144 for chronic kidney disease, and GenSci133 for osteoporosis. These add future revenue sources, though trials can still fail.

    These pipeline advances are the main positive driver and show where future growth may come from.

  • Osteoporosis Drug Trial Approved GenSci133 injection received clinical trial approval for osteoporosis. It is a long-acting biologic that may be injected only every three to six months, which could make it easier for patients to use and strengthen the company's endocrine and metabolic product line.

    This is a concrete regulatory step forward for a key pipeline asset.

  • Global Rights Deal and New Approval The company is paying $30 million plus up to $70 million in milestones for worldwide rights to Megace, a drug already on China's insurance list. Separately, its leuprorelin injection for prostate cancer received a registration certificate, expanding the marketed product portfolio.

    These two events add global reach and a new approved product, supporting future sales.

August 2026
▲3▼1

Profit Halved, but Drug Pipeline and Global Deal Advance

  • Interim Profit Halved First-half 2026 net profit fell 51.64% to 475 million yuan as revenue dropped 16.06%. This is the single biggest drag on the stock because it shows the core business is shrinking, even though operating cash flow rose 40.92%.

    The profit decline is the main negative force on the stock this period.

  • Pipeline Wins Keep Coming The company's GeneScience unit won Chinese regulatory acceptance or approval for four new drug candidates: Jintuoximab for gastric cancer, GenSci136 for lupus, GenSci144 for chronic kidney disease, and GenSci133 for osteoporosis. These add future revenue sources, though trials can still fail.

    These pipeline advances are the main positive driver and show where future growth may come from.

  • Osteoporosis Drug Trial Approved GenSci133 injection received clinical trial approval for osteoporosis. It is a long-acting biologic that may be injected only every three to six months, which could make it easier for patients to use and strengthen the company's endocrine and metabolic product line.

    This is a concrete regulatory step forward for a key pipeline asset.

  • Global Rights Deal and New Approval The company is paying $30 million plus up to $70 million in milestones for worldwide rights to Megace, a drug already on China's insurance list. Separately, its leuprorelin injection for prostate cancer received a registration certificate, expanding the marketed product portfolio.

    These two events add global reach and a new approved product, supporting future sales.

Latest
▲3▼1

Profit Halved, but Drug Pipeline and Global Deal Advance

  • Interim Profit Halved First-half 2026 net profit fell 51.64% to 475 million yuan as revenue dropped 16.06%. This is the single biggest drag on the stock because it shows the core business is shrinking, even though operating cash flow rose 40.92%.

    The profit decline is the main negative force on the stock this period.

  • Pipeline Wins Keep Coming The company's GeneScience unit won Chinese regulatory acceptance or approval for four new drug candidates: Jintuoximab for gastric cancer, GenSci136 for lupus, GenSci144 for chronic kidney disease, and GenSci133 for osteoporosis. These add future revenue sources, though trials can still fail.

    These pipeline advances are the main positive driver and show where future growth may come from.

  • Osteoporosis Drug Trial Approved GenSci133 injection received clinical trial approval for osteoporosis. It is a long-acting biologic that may be injected only every three to six months, which could make it easier for patients to use and strengthen the company's endocrine and metabolic product line.

    This is a concrete regulatory step forward for a key pipeline asset.

  • Global Rights Deal and New Approval The company is paying $30 million plus up to $70 million in milestones for worldwide rights to Megace, a drug already on China's insurance list. Separately, its leuprorelin injection for prostate cancer received a registration certificate, expanding the marketed product portfolio.

    These two events add global reach and a new approved product, supporting future sales.

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.CG)

Q3 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

August 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

Latest
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.